Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Race Oncology Ltd has made significant strides in its Phase 1 clinical trial of RC220 in combination with doxorubicin for patients with advanced solid tumors. The company received ethics and regulatory approvals for trial sites, with patient screening underway and treatment expected to begin soon. The company is financially stable with $17.12 million in cash, ensuring funding for its clinical programs through CY2026. Additionally, Race Oncology was added to the All Ordinaries Index, highlighting its growing presence in the Australian equities market.
More about Race Oncology Ltd.
Race Oncology Ltd is a company operating in the biotechnology industry, focusing on the development of cancer treatments. Its primary product is RC220, a cardioprotective and anticancer agent, with a market focus on advanced solid tumors.
YTD Price Performance: -31.48%
Average Trading Volume: 109,113
Technical Sentiment Signal: Buy
Current Market Cap: A$160.7M
Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.